Wve-120102    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
8ハンチントン病9

8. ハンチントン病 [臨床試験数:197,薬物数:171(DrugBank:54),標的遺伝子数:82,標的パスウェイ数:144
Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
9 / 197 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-002178-30-DE
(EUCTR)
28/07/202012/06/2020A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120102
Product Code: WVE-120102
INN or Proposed INN: WVE-120102
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
70Phase 2France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
2EUCTR2019-002178-30-DK
(EUCTR)
22/01/202018/09/2019A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120102
Product Code: WVE-120102
INN or Proposed INN: WVE-120102
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
70Phase 2France;Canada;Poland;Australia;Denmark;Germany;United Kingdom
3EUCTR2019-002178-30-PL
(EUCTR)
29/10/201913/08/2019A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120102
Product Code: WVE-120102
INN or Proposed INN: WVE-120102
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
70Phase 2France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
4NCT04617860
(ClinicalTrials.gov)
September 24, 201930/10/2020Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients With Huntington's DiseaseHuntington DiseaseDrug: WVE-120102Wave Life Sciences Ltd.NULLEnrolling by invitationN/AN/AAll60Phase 1;Phase 2Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
5EUCTR2016-005142-39-FR
(EUCTR)
09/07/201921/05/2019A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
WAVE Life Sciences LtdNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
48Phase 1;Phase 2United States;France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2016-005142-39-DK
(EUCTR)
26/02/201920/12/2018A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120102
Product Code: WVE-120102
INN or Proposed INN: WVE-120102
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 1;Phase 2United States;France;Canada;Poland;Australia;Denmark;Germany;United Kingdom
7EUCTR2016-005142-39-GB
(EUCTR)
02/08/201819/05/2017A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
48Phase 1;Phase 2France;United States;Canada;Poland;Denmark;Australia;Germany;United Kingdom
8NCT03225846
(ClinicalTrials.gov)
July 17, 201717/7/2017Safety and Tolerability of WVE-120102 in Patients With Huntington's DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's DiseaseHuntington's DiseaseDrug: WVE-120102;Drug: PlaceboWave Life Sciences Ltd.NULLRecruiting25 Years65 YearsAll60Phase 1;Phase 2Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
9EUCTR2016-005142-39-DE
(EUCTR)
04/06/2019A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120102
Product Code: WVE-120102
INN or Proposed INN: WVE-120102
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 1;Phase 2France;United States;Canada;Poland;Denmark;Australia;Germany;United Kingdom